Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial)

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 9, 2011, Pages 2083-2091

  Thorne Humphrey, L M ^a,b   Goralski, K B ^a,c   Slayter, K L ^a,b,d   Hatchette, T F ^a,b   Johnston, B L ^a,b   McNeil, S A ^a,b,d,e  

^a DALHOUSIE UNIVERSITY   (Canada)

^b QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d Canadian Center for Vaccinology Dalhousie University Halifax   (Canada)

^e IWK HEALTH CENTRE   (Canada)

Author keywords

Body mass index; Body weight; Obese; PK

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; OSELTAMIVIR;

ABDOMINAL DISCOMFORT; ADULT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; MALE; MORBID OBESITY; MORNING DOSAGE; NAUSEA; SINGLE DRUG DOSE; STEADY STATE; VOMITING;

ADULT; ANTIVIRAL AGENTS; AREA UNDER CURVE; BIOTRANSFORMATION; BODY MASS INDEX; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; OBESITY, MORBID; OSELTAMIVIR; PRODRUGS; YOUNG ADULT;

EID: 80051684457     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr257     Document Type: Article

References (38)

1. Doucette KE, Aoki FY. Oseltamivir: a clinical and pharmacological perspective. Expert Opin Pharmacother 2001; 2: 1671-83.
2. Jefferson T, Jones M, Doshi P et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ 2009; 339: b5106.
3. Hoffman-La Roche Tamifluw (Oseltamivir Phosphate Capsule) Product Monograph. 2009.
4. CDC. Updated Interim Recommendations for the Use of Antiviral Medications in the Treatment and Prevention of Influenza for the 2009- 2010 Season. http://www.cdc.gov/h1n1flu/recommendations.htm (2 May 2011, date last accessed).
5. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010; 362: 1708-19.
6. WHO. Weekly Update On Oseltamivir Resistance To Pandemic Influenza A (H1N1) 2009 Viruses. http://www.who.int/csr/disease/swineflu/oseltamivirresistant20100611.pdf (2 May 2011, date last accessed).
7. Napolitano LM, Park PK, Sihler KC et al. Intensive-care patients with severe novel influenza A (H1N1) virus infection - Michigan, June 2009. MMWR Morb Mortal Wkly Rep 2009; 58: 749-52.
8. Jain S, Kamimoto L, Bramley AM et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009; 361: 1935-44.
9. Louie JK, Acosta M, Winter K et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A (H1N1) infection in California. JAMA 2009; 302: 1896-902.
10. Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy 2007; 27: 1081-91.
11. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010; 49: 71-87.
12. Bearden DT, Rodvold KA. Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics. Clin Pharmacokinet 2000; 38: 415-26.
13. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 2000; 39: 215-31.
14. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
15. Hill G, Cihlar T, Oo C et al. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab Dispos 2002; 30: 13-9.
16. Heinig K, Bucheli F. Sensitive determination of oseltamivir and oseltamivir carboxylate in plasma, urine, cerebrospinal fluid and brain by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 876: 129-36.
17. Wiltshire H, Wiltshire B, Citron A et al. Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine. J Chromatogr B Biomed Sci Appl 2000; 745: 373-88.
18. Janmahasatian S, Duffull SB, Ash S et al. Quantification of lean bodyweight. Clin Pharmacokinet 2005; 44: 1051-65.
19. Han PY, Duffull SB, Kirkpatrick CM et al. Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther 2007; 82: 505-8.
20. Freedman DS, Khan LK, Serdula MK et al. Trends and correlates of class 3 obesity in the United States from 1990 through 2000. JAMA 2002; 288: 1758-61.
21. Katzmarzyk PT, Mason C. Prevalence of class I, II and III obesity in Canada. CMAJ 2006; 174: 156-7.
22. Poggesi I, Benedetti MS, Whomsley R et al. Pharmacokinetics in special populations. Drug Metab Rev 2009; 41: 422-54.
23. Davies BE. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J Antimicrob Chemother 2010; 65 Suppl 2: ii5-10.
24. Shi D, Yang J, Yang D et al. Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J Pharmacol Exp Ther 2006; 319: 1477-84.
25. Ariano RE, Sitar DS, Zelenitsky SA et al. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. CMAJ 2010; 182: 357-63.
26. He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 1999; 37: 471-84.
27. Massarella JW, He GZ, Dorr A et al. The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers. J Clin Pharmacol 2000; 40: 836-43.
28. Taylor WR, Thinh BN, Anh GT et al. Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza. PLoS One 2008; 3: e3410.
29. Emery MG, Fisher JM, Chien JY et al. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology 2003; 38: 428-35.
30. de la Maza MP, Hirsch S, Petermann M et al. Changes in microsomal activity in alcoholism and obesity. Alcohol Clin Exp Res 2000; 24: 605-10.
31. Mathijssen RH, Sparreboom A. Influence of lean body weight on anticancer drug clearance. Clin Pharmacol Ther 2009; 85: 23; author reply 4.
32. Renton KW. Regulation of drug metabolism and disposition during inflammation and infection. Expert Opin Drug Metab Toxicol 2005; 1: 629-40.
33. Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb Mortal Wkly Rep 2009; 58: 433-5.
34. Govorkova EA, Ilyushina NA, McClaren JL et al. Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. Antimicrob Agents Chemother 2009; 53: 3088-96.
35. Baz M, Abed Y, Papenburg J et al. Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. N Engl J Med 2009; 361: 2296-7.
36. Memoli MJ, Hrabal RJ, Hassantoufighi A et al. Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin Infect Dis 2010; 50: 1252-5.
37. Speers DJ, Williams SH, Pinder M et al. Oseltamivir-resistant pandemic (H1N1) 2009 influenza in a severely ill patient: the first Australian case. Med J Aust 2010; 192: 166-8.
38. Eisenberg EJ, Bidgood A, Cundy KC. Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104. Antimicrob Agents Chemother 1997; 41: 1949-52.